← Oncology Approval Tracker

FDA DECISION ·

Augtyro

repotrectinib · Bristol Myers Squibb

FDA approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with ROS1-positive non-small cell lung cancer that is locally advanced or metastatic.

LAMPGEN ANALYSIS

Why it matters

A ROS1 inhibitor expanded the targeted treatment options for this molecular subtype.

What research teams should watch

Document the ROS1 result and prior targeted therapy to interpret cohort-specific evidence.

PRIMARY RECORDS

Sources